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Results
Out of 699 patients who underwent ET over the study period, 422 met our inclusion criteria. A total of 253 patients (60%) received IV-tPA+ET, and 169 (40%), ET alone. ET-alone patients were IV-tPA-ineligible either because of presentation >4.5 hours (n=66, 39%) or because of nontime-based reasons (n=103, 61%). Baseline characteristics, efficacy, and safety end points are shown in Table. Combined IV-tPA+ET patients were slightly younger (64.9±15.2 versus 67.9±14.9 years; P=0.05), more often males (56% versus 44%; P=0.01), and had less hypertension (70% versus 81%; P=0.02) and vertebrobasilar occlusions (3% versus 8%; P=0.02) as compared with ET-alone/IV-tPA-ineligible patients. There were no statistical difference in the rates of 90-day modified Rankin scale score ≤2 (45% versus 38%; P=0.21), successful reperfusion (83% versus 80%; P=0.52), or any PH (3% versus 5%; P=0.21) across the 2 groups. Unadjusted 90-day mortality was higher with ET-alone (21% versus 34%; P<0.01); however, IV-tPA ineligibility was not associated with 90-day mortality on multivariable analyses. Overall, these results were consistent across the different time epochs (Table) . There were no identified predictors of any PH in the current analysis likely because of its overall low frequency and the cohort size. Older age (OR 1.05, 95% CI 1.03-1.08), higher glucose levels on admission (OR 1.00, 95% CI 1.00-1.01), higher baseline National Institutes of Health Stroke Scale (OR 1.01, 95% CI 1.03-1.16), lower baseline ASPECTS (OR 0.75, 95% CI 0.62-0.90), failure to achieve modified Treatment in Cerebral Ischemia 2b-3 reperfusion (OR 0.38, 95% CI 0.19-0.74), and any PH (OR 4.39, 95% CI 1.32-14.57) were independently associated with 90-day mortality. Notably, there was no association between the use of IV-tPA and 90-day mortality on logistic regression (OR 0.62, 95% CI 0.34-1.12). Sensitivity analyses were performed forcing the use of IV-tPA into the models and failed to demonstrate its association with any of the study outcomes.
Discussion
Intravenous tPA was administered in 73% to 100% of the patients enrolled in the recent randomized trials demonstrating the superiority of ET over medical therapy. 5 Moreover, patients who did not qualify for IV-tPA for reasons other than time to presentation, such as anticoagulation use, bleeding diathesis, recent surgery, intracranial or systemic bleeding, trauma, or recent stroke, were for the most part excluded from these trials. Consequently, Level 1a data to support ET in IV-tPA-ineligible patients is still lacking, and these patients have received more limited attention in the recently published guidelines. 2 The current study revealed that the benefit of ET in IV-tPA-ineligible patients seems to be comparable to those treated with IV-tPA+ET, despite similar times to ET. These results are consistent with a recent multicenter study of 130 IV-tPA-ineligible patients with anterior circulation strokes treated with stent retriever within 4.5 hours of symptom onset. 6 Interestingly, smoking status was independently associated with higher rates of successful reperfusion, as previously described. 7 Our study has limitations, mostly inherent to its retrospective design and limited sample size. It is possible that the 7% difference across the groups could reach statistical significance with a larger sample size. There were mild imbalances in terms of age, sex, and the prevalence of hypertension and vertebrobasilar occlusions. The higher 90-day mortality rate in the IV-tPAineligible patients is likely explained by the older age and higher frequency of vertebrobasilar occlusion in the IV-tPA-ineligible group because no association was seen on multivariable analysis.
Our findings suggest that patients who are ineligible for IV-tPA who presented to ET within 6 hours of symptom onset can safely undergo ET and seem to achieve similar rates of reperfusion and good outcome compared with IV-tPA+ET patients within the same time frame. Given the known poor outcomes in large vessel occlusion strokes treated with IV-tPA only and the superiority of IV-tPA over medical treatment alone, it is unlikely that a randomized trial comparing ET with medical treatment will be ever performed for IV-tPA-ineligible patients. As such, we hope that our study will add to the yet scarce literature on this patient population and will further support the pursuit of endovascular reperfusion in IV-tPA-ineligible patients. 
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